Prashasti Sinha
Overview
Explore the profile of Prashasti Sinha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
1
Followers
0
Related Specialties
Related Specialties
Co-Authors
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sinha P, Yadav A
Mol Divers
. 2024 Apr;
29(1):241-254.
PMID: 38615110
Cimicifugae is a commonly used treatment for breast cancer, but the specific molecular mechanisms underlying its effectiveness remain unclear. In this research, we employ a combination of network pharmacology, molecular...
2.
Repurposing integrase inhibitors against human T-lymphotropic virus type-1: a computational approach
Sinha P, Yadav A
J Biomol Struct Dyn
. 2024 Jan;
:1-12.
PMID: 38234060
Adult T-cell Lymphoma (ATL) is caused by the delta retrovirus family member known as Human T-cell Leukaemia Type I (HTLV-1). Due to the unavailability of any cure, the study gained...
3.
Sinha P, Yadav A
J Biomol Struct Dyn
. 2023 Nov;
42(24):13663-13679.
PMID: 37921740
Nipah virus (NiV) is one of the most common viral diseases affecting the brain and nervous system of the body. To date, there is no significant antiviral drug specifically designed...
4.
Sinha P, Yadav A
J Biomol Struct Dyn
. 2023 Aug;
42(13):7037-7053.
PMID: 37580968
The quest to identify antiviral drug candidates for dengue and rabies viral diseases is a great challenge for the researchers. While different research is being conducted on the repurposed drugs...
5.
Sinha P, Yadav A
J Biomol Struct Dyn
. 2023 Jul;
42(10):5001-5014.
PMID: 37517053
Rotavirus is one of the most common gastrointestinal viral diseases. Till date, there are only two vaccines available in the markets, which are specifically to be administered to young babies....
6.
Sinha P, Yadav A
J Mol Model
. 2023 Apr;
29(5):130.
PMID: 37017775
Context: The unavailability of target-specific antiviral drugs for SARS-CoV-2 viral infection kindled the motivation to virtually design derivatives of 6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as potential antiviral inhibitors against the concerned virus. The molecular...
7.
Sinha P, Yadav A
J Biomol Struct Dyn
. 2023 Mar;
41(23):14092-14102.
PMID: 36907647
A hit compound was designed using Fragment Based Drug Designing (FBDD) approach, density functional theory (DFT) calculations were performed to find the structural and electronic properties. Additionally, pharmacokinetic properties were...